Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine

A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation

Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,253 · see citing works

Bupropion: a review of its mechanism of antidepressant activity.

Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680 · see citing works

Neuronal Nicotinic Acetylcholine Receptors

Lindstrom, J. (1996) · Springer eBooks · doi:10.1007/978-1-4899-1775-1_10 · Cited by 382 · see citing works

Neurons Can Maintain Multiple Classes of Nicotinic Acetylcholine Receptors Distinguished by Different Subunit Compositions

Conroy, W. G., & Berg, D. K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.9.4424 · Cited by 297 · see citing works

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

Rose, J. E., Behm, F. M., Westman, E. C., Levin, E. D., STEIN, R. M., & Ripka, G. V. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.105 · Cited by 248 · see citing works

Neurotransmitter-gated ion channels as unconventional allosteric proteins

Galzi, J., & Changeux, J. (1994) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(94)90218-6 · Cited by 200 · see citing works

Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line

Lukas, R. J., Norman, S. A., & Lucero, L. M. (1993) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1993.1001 · Cited by 192 · see citing works

100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.

Popik, P., Layer, R. T., & Skolnick, P. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06842-5 · Cited by 183 · see citing works

Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers

Hsyu, P., Singh, A. K., Giargiari, T. D., Dunn, J. A., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04361.x · Cited by 137 · see citing works

Bupropion in Depression

Golden, R. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260055007 · Cited by 122 · see citing works

Functional expression of nicotinic acetylcholine receptors containing rat α7 subunits in human SH‐SY5Y neuroblastoma cells

Puchacz, E., Buisson, B., Bertrand, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01108-7 · Cited by 107 · see citing works

The Phencyclidine-Glutamate Model of Schizophrenia

Halberstadt, A. L. (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199506000-00004 · Cited by 104 · see citing works

Heterogeneity and Regulation of Nicotinic Acetylcholine Receptors

Lukas, R. J., & Bencherif, M. (1992) · International review of neurobiology · doi:10.1016/s0074-7742(08)60097-5 · Cited by 95 · see citing works

Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs.

Suckow, R. F., Smith, T. M., Perumal, A. S., & Cooper, T. B. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08996-2 · Cited by 85 · see citing works

Sites of action of phencyclidine. II. Interaction with the ionic channel of the nicotinic receptor.

Albuquerque, E. X., Tsai, M.-C., Aronstam, R. S., et al. (1980) · PubMed · Cited by 76 · see citing works

A Review of NMDA Receptors and the Phencyclidine Model of Schizophrenia

Thornberg, S. A., & Saklad, S. R. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02920.x · Cited by 73 · see citing works

Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration

Hough, L. B., Pearl, S. M., & Glick, S. D. (1996) · Life Sciences · doi:10.1016/0024-3205(95)02322-4 · Cited by 72 · see citing works

Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma.

Lukas, R. J. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20697-8 · Cited by 69 · see citing works

Characterization of Curaremimetic Neurotoxin Binding Sites on Membrane Fractions Derived from the Human Medulloblastoma Clonal Line, TE671

Lukas, R. J. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb08516.x · Cited by 62 · see citing works

Ibogaine: A Potent Noncompetitive Blocker of Ganglionic/Neuronal Nicotinic Receptors

Badio, B., Padgett, W. L., & Daly, J. W. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.1.1 · Cited by 53 · see citing works

Sites of action of phencyclidine. I. Effects on the electrical excitability and chemosensitive properties of the neuromuscular junction of skeletal muscle.

Tsai, M.-C., Albuquerque, E. X., Aronstam, R. S., et al. (1980) · PubMed · Cited by 39 · see citing works

The "calcium antagonist" TMB-8 [3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester] is a potent, non-competitive, functional antagonist at diverse nicotinic acetylcholine receptor subtypes.

Bencherif, M., Eisenhour, C. M., Prince, R. J., et al. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12200-3 · Cited by 35 · see citing works

Functional evidence for a second binding site of nicotinic antagonists using phencyclidine derivatives

Kloog, Y., Gabrialevitz, A., Kalir, A., et al. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90456-8 · Cited by 22 · see citing works

Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release

Schneider, A. S., Nagel, J. E., & Mah, S. J. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00815-1 · Cited by 20 · see citing works

CSF phencyclidine

Donaldson, J. O., & Baselt, R. C. (1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.10.1341 · Cited by 13 · see citing works

Sites of Action of Phencyclidine

Albuquerque, E. X., Tsai, M.-C., Aronstam, R. S., et al. (1980) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14352-6 · Cited by 13 · see citing works

Inhibitory effects of psychotomimetic σ ligands on nicotine-induced K+ flux from differentiated PC12 cells

Yamamoto, H., Sagi, N., Yamamoto, T., Goji, Y., Okuwa, M., Yoshii, M., & Moroji, T. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90783-4 · Cited by 10 · see citing works

Psychopharmacology of phencyclidine.

Marwah, J., & Pitts, D. K. (1986) · PsycEXTRA Dataset · doi:10.1037/e471772004-001 · Cited by 4 · see citing works

Inhibition and impulsivity: behavioral and neural basis of response control

Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921 · see citing works

Antidepressants for smoking cessation

Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567 · see citing works

Bupropion is a nicotinic antagonist

Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509 · see citing works

Effect of nicotine and nicotinic receptors on anxiety and depression

Picciotto, M. R., Brunzell, D. H., & Caldarone, B. J. (2002) · Neuroreport · doi:10.1097/00001756-200207020-00006 · Cited by 483 · see citing works

Antidepressants for smoking cessation

Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352 · see citing works

Nicotinic acetylcholine receptors as targets for antidepressants

Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279 · see citing works

Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent

Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259 · see citing works

Tobacco addiction

Hatsukami, D. K., Stead, L. F., & Gupta, P. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60871-5 · Cited by 227 · see citing works

Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat

Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223 · see citing works

Does Acceptance and Relationship Focused Behavior Therapy Contribute to Bupropion Outcomes? A Randomized Controlled Trial of Functional Analytic Psychotherapy and Acceptance and Commitment Therapy for Smoking Cessation

Gifford, E. V., Kohlenberg, B. S., Hayes, S. C., Pierson, H. M., Piasecki, M. P., Antonuccio, D. O., & Palm, K. M. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.002 · Cited by 200 · see citing works

Nicotinic treatment of Alzheimer’s disease

Newhouse, P. A., Potter, A., Kelton, M., & Corwin, J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01069-6 · Cited by 146 · see citing works

Nicotinic–serotonergic interactions in brain and behaviour

Seth, P., Cheeta, S., Tucci, S., & File, S. E. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00715-8 · Cited by 145 · see citing works

Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal

De Biasi, M., & Salas, R. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-mr-355 · Cited by 95 · see citing works

Central Nervous System Biogenic Amine Targets for Control of Appetite and Energy Expenditure

Nelson, D. L., & Gehlert, D. R. (2006) · Endocrine · doi:10.1385/endo:29:1:49 · Cited by 78 · see citing works

Mechanistic insights into nicotine withdrawal

Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66 · see citing works

Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats

Palmatier, M. I., Levin, M. E., Mays, K. L., Donny, E. C., Caggiula, A. R., & Sved, A. F. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1666-5 · Cited by 40 · see citing works

Bupropion hydrochloride produces conditioned hyperactivity in rats

Wilkinson, J. L., & Bevins, R. A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.01.003 · Cited by 18 · see citing works

[Antibody against synthetic peptide corresponding to alpha-subunit residues 128-142 of nicotinic acetylcholine receptor (AChR): the significance in myasthenia gravis (MG)].

Shibuya, N., Kanazawa, H., & Uyemura, K. (1988) · PubMed

Effects of acute denervation on ratio change of nicotinic acetylcholine receptor subtypes in the rat gastrocnemius muscle

Shiton, L. (2008) · Shiyong yixue zazhi · Cited by 1 · see citing works

α -Bungarotoxin binding to human muscle acetylcholine receptor: measurement of affinity, delineation of AChR subunit residues crucial to binding, and protection of AChR function by synthetic peptides

Vincent, A. C., Jacobson, L. W., & Curran, L. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00118-6 · Cited by 21 · see citing works

Antigenic specificity of acetylcholine receptor in developing muscle

Souroujon, M. C., Pizzighella, S., Mochly‐Rosen, D., et al. (1985) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(85)80056-4 · Cited by 13 · see citing works

α7 Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment

Thomsen, M. S., Christensen, D. Z., Hansen, H. H., Redrobe, J. P., & Mikkelsen, J. D. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.02.003 · Cited by 78 · see citing works